Table 3

Association of alpha 1-antitrypsin protease inhibitor (PI)-MZ status and standardised lung function adjusted for age, sex, height and height-squared

OutcomeCohortRegression coefficient (95% CI)
Maximum FEV1BO0.17 (−0.40 to 0.74)
CaPS0.09 (−0.12 to 0.30)
ELSA0.06 (−0.05 to 0.16)
HAS0.11 (−0.34 to 0.56)
HCS−0.01 (−0.15 to 0.12)
LBC19210.09 (−0.27 to 0.44)
NSHD0.08 (−0.08 to 0.23)
WHII0.11 (−0.00 to 0.21)
Combined FE0.07* (0.01 to 0.12)
Combined RE0.07* (0.01 to 0.12)
Estimated var†1.03e−17 (1.80e−32 to 5.87e−03)
Maximum FVCBO0.06 (−0.43 to 0.56)
CaPS0.13 (−0.08 to 0.34)
ELSA0.04 (−0.06 to 0.14)
HAS0.35 (−0.04 to 0.74)
HCS0.07 (−0.05 to 0.18)
LBC19210.10 (−0.23 to 0.44)
NSHD0.08 (−0.06 to 0.23)
WHII0.10 (−0.00 to 0.20)
Combined FE0.08** (0.03 to 0.13)
Combined RE0.08** (0.03 to 0.13)
Estimated var†1.25e−13 (5.20e−27 to 3.01e+00)
  • *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

  • †Estimated variance of the random slope on carrier status modelled by the RE model.

  • BO, Boyd Orr; CaPS, Caerphilly Prospective Study; ELSA, English Longitudinal Study of Ageing; FE, fixed effect; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HAS; Hertfordshire Ageing Study; HCS, Hertfordshire Cohort Study; LBC1921, Lothian Birth Cohort 1921; NSHD, MRC National Survey of Health and Development; RE, random effect; WHII, Whitehall II Study.